Pharming, HyupJin announce receipt of South Korean marketing authorization for Ruconest

21 December 2015

Netherlands-based Pharming Group NV (Euronext Amsterdam: PHARM) and its partner, HyupJin Corporation, a Seoul-based South Korean specialty pharma company, said that HyupJin has received the marketing authorization for Ruconest (recombinant human C1 inhibitor) in South Korea.

Sijmen de Vries, chief executive of Pharming, said: “HyupJin is a well-established and experienced company with a proven track record in South Korea. We look forward to them now extending the commercialization of Ruconest by providing HAE patients in South Korea with a new, safe and effective treatment to treat their HAE attacks.”

Ruconest is approved for the treatment of acute angioedema attacks in adult patients with hereditary angioedema (HAE). Effectiveness was not established in HAE patients with laryngeal and oro-pharyngeal attacks. HyupJin will now seek reimbursement for Ruconest in South Korea.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK